Safety, tolerability, and immunogenicity of a CpG/Alum adjuvanted SARS-CoV-2 recombinant protein vaccine (ZR202-CoV) in healthy adults: Preliminary report of a phase 1, randomized, double-blind, placebo-controlled, dose-escalation trial

Author:

Feng Guang-Wei1,Wang Zhong-Fang23,He Peng4,Lan Qin-Ying5,Ni Ling6,Yang Ya-Zheng6,Wang Chen-Fei4,Cui Ting-Ting2,Huang Li-Li1,Yan Yong-Qiang7,Jiang Zhi-Wei8,Yang Qing5,Yu Bang-Wei5,Han Xi5,Chen Jing-Jing9,Yang Shu-Yuan9,Yuan Lin9,Zhou Ling-Yun5,Liu Ge5,Li Ke5,Huang Zhen9,Zhao Jin-Cun23,Hu Zhong-Yu4,Xie Zhi-Qiang1

Affiliation:

1. Vaccine Clinical Research Center, Henan Provincial Center for Disease Control and Prevention, Zhenzhou, HA, China

2. State Key Laboratory of Respiratory Disease & National Clinical Research Center for Respiratory Disease, Guangzhou Institute of Respiratory Health, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou, GD, China

3. Division of Drug and Vaccine Research, Guangzhou Laboratory, Bioland, Guangzhou, GD, China

4. Department of Hepatitis and Enterovirus Vaccine, National Institutes for Food and Drug Control, Beijing, China

5. R&D Department, Shanghai Zerun Biotechnology Co. Ltd, Shanghai, China

6. School of Medicine, Tsinghua University, Beijing, China

7. Vaccine Program Office, Xiangcheng County Center for Disease Control and Prevention, Xiangcheng, HA, China

8. Statistics and Decision Sicence, Beijing Key Tech Statistical Consulting Co. Ltd, Beijing, China

9. R&D Department, Walvax Biotechnology Co. Ltd, Kunming, Yunnan, China

Funder

Coalition for Epidemic Preparedness Innovations

Joint Construction Project of Henan Provincial Medical Science and Technology Research Plan in 2021

Publisher

Informa UK Limited

Subject

Pharmacology,Immunology,Immunology and Allergy

Reference20 articles.

1. Use of Chest CT in Combination with Negative RT-PCR Assay for the 2019 Novel Coronavirus but High Clinical Suspicion

2. SARS-CoV-2 Vaccine Development: Current Status

3. Recombinant vaccines for COVID-19

4. Development of recombinant COVID-19 vaccine based on CHO-produced, prefusion spike trimer and alum/CpG adjuvants

5. GSK. Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine; [accessed 2022 Aug 29]. https://www.gsk.com/en-gb/media/press-releases/sanofi-gsk-first-to-report.

Cited by 2 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3